Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study

Regine Schneider-Stock, Carsten Boltze, Jerzy Lasota, Brigitte Peters, Christopher Corless, Petra Ruemmele, Luigi Terracciano, Matthias Pross, Luigi Insabato, Dolores Di Vizio, Igor Iesalnieks, Stefan Dirnhofer, Arndt Hartmann, Michael Heinrich, Markku Miettinen, Albert Roessner, Luigi Tornillo

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50% of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two "antitypes," whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The "type" whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P <0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number2 I
StatePublished - Jan 15 2005

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasm Metastasis
Necrosis
Neoplasms
Proteins
Survival Analysis
Stomach
Regression Analysis
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schneider-Stock, R., Boltze, C., Lasota, J., Peters, B., Corless, C., Ruemmele, P., ... Tornillo, L. (2005). Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study. Clinical Cancer Research, 11(2 I), 638-645.

Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors : A tissue microarray study. / Schneider-Stock, Regine; Boltze, Carsten; Lasota, Jerzy; Peters, Brigitte; Corless, Christopher; Ruemmele, Petra; Terracciano, Luigi; Pross, Matthias; Insabato, Luigi; Di Vizio, Dolores; Iesalnieks, Igor; Dirnhofer, Stefan; Hartmann, Arndt; Heinrich, Michael; Miettinen, Markku; Roessner, Albert; Tornillo, Luigi.

In: Clinical Cancer Research, Vol. 11, No. 2 I, 15.01.2005, p. 638-645.

Research output: Contribution to journalArticle

Schneider-Stock, R, Boltze, C, Lasota, J, Peters, B, Corless, C, Ruemmele, P, Terracciano, L, Pross, M, Insabato, L, Di Vizio, D, Iesalnieks, I, Dirnhofer, S, Hartmann, A, Heinrich, M, Miettinen, M, Roessner, A & Tornillo, L 2005, 'Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study', Clinical Cancer Research, vol. 11, no. 2 I, pp. 638-645.
Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless C, Ruemmele P et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study. Clinical Cancer Research. 2005 Jan 15;11(2 I):638-645.
Schneider-Stock, Regine ; Boltze, Carsten ; Lasota, Jerzy ; Peters, Brigitte ; Corless, Christopher ; Ruemmele, Petra ; Terracciano, Luigi ; Pross, Matthias ; Insabato, Luigi ; Di Vizio, Dolores ; Iesalnieks, Igor ; Dirnhofer, Stefan ; Hartmann, Arndt ; Heinrich, Michael ; Miettinen, Markku ; Roessner, Albert ; Tornillo, Luigi. / Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors : A tissue microarray study. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 2 I. pp. 638-645.
@article{a3bbe6f106d14b8eaa21880e4bb7cb0b,
title = "Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study",
abstract = "Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50{\%} of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two {"}antitypes,{"} whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The {"}type{"} whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P <0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.",
author = "Regine Schneider-Stock and Carsten Boltze and Jerzy Lasota and Brigitte Peters and Christopher Corless and Petra Ruemmele and Luigi Terracciano and Matthias Pross and Luigi Insabato and {Di Vizio}, Dolores and Igor Iesalnieks and Stefan Dirnhofer and Arndt Hartmann and Michael Heinrich and Markku Miettinen and Albert Roessner and Luigi Tornillo",
year = "2005",
month = "1",
day = "15",
language = "English (US)",
volume = "11",
pages = "638--645",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2 I",

}

TY - JOUR

T1 - Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors

T2 - A tissue microarray study

AU - Schneider-Stock, Regine

AU - Boltze, Carsten

AU - Lasota, Jerzy

AU - Peters, Brigitte

AU - Corless, Christopher

AU - Ruemmele, Petra

AU - Terracciano, Luigi

AU - Pross, Matthias

AU - Insabato, Luigi

AU - Di Vizio, Dolores

AU - Iesalnieks, Igor

AU - Dirnhofer, Stefan

AU - Hartmann, Arndt

AU - Heinrich, Michael

AU - Miettinen, Markku

AU - Roessner, Albert

AU - Tornillo, Luigi

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50% of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two "antitypes," whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The "type" whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P <0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.

AB - Despite clearly defined histologic criteria, the prediction of tumor behavior for patients with gastrointestinal stromal tumors (GIST) still poses a challenge to pathologists. Therefore, searching for alternative markers that allow for better prognostic evaluation is an important task. To determine the practicability of immunohistochemical staining for p16 in clinical cases, we examined p16 protein expression in a group of 284 GISTs, a subset of which had long-term follow-up (median, 45 months; range, 1-204 months). P16 protein expression was ascertained on tissue microarrays as well as on standard sections. Survival analyses were carried out in 157 patients. P16 loss was found in 50% of GISTs, there being no correlation with age, sex, histologic subtype, signs of necrosis, or metastases. Patients having p16-negative tumors had a worse prognosis than those with p16-positive tumors (P = 0.012) with a 2.3-fold relative increased risk of dying of disease. P16 loss identified a subgroup of gastric tumors with a worse prognosis (P = 0.03). The multivariate configural frequency analysis identified two "antitypes," whose observed frequency was found to be significantly lower than the expected frequency [i.e., marker combinations: p16 positive, no metastases, and death of disease and p16 loss, metastases, and still alive]. The "type" whose observed frequency was significantly higher than the expected frequency consisted of the following marker pattern: p16 loss, necrosis, and death of disease (P <0.001). In the multivariate Cox regression analysis, p16 loss, necrosis, and metastases each had independent prognostic value. P16 loss is a common molecular abnormality in GISTs and might be used in routine diagnosis to identify patients with high-risk tumors.

UR - http://www.scopus.com/inward/record.url?scp=19944427609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427609&partnerID=8YFLogxK

M3 - Article

C2 - 15701851

AN - SCOPUS:19944427609

VL - 11

SP - 638

EP - 645

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2 I

ER -